drugset / Trial / NCT04675697
Anlotinib Plus Platinum-etoposide in First-line of Extensive-stage Small-cell Lung Cancer
Phase 2
Unknown
36 enrolled
Xiangya Hospital of Central South University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
Anlotinib is a novel multi-target tyrosine kinase inhibitor (TKI) for tumor angiogenesis and tumor cell proliferation. The efficacy of Anlotinib as a third-line or beyond therapy for SCLC was confirmed in the ALTER1202 trial. The aim of this trial was to investigate the prognostic value of Anlotinib plus platinum-etoposide in first-line treatment of extensive-stage SCLC patients.
Timeline
- Start
- 2019-01-24
- Primary completion
- 2020-12-31
- Completion
- 2021-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Carboplatin | Small molecule | 6 unknown | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 80 mg/m2 | — |
| Background | Etoposide | Small molecule | 100 mg/m2 | — |